Synergetics v. Alcon Laboratories
This article was originally published in The Gray Sheet
Executive Summary
Alcon will pay Synergetics $32 million for the right to sell certain Synergetics products on a co-exclusive basis under a licensing deal that also settles all pending litigation between the firms, announced April 27. Other terms were not disclosed. Synergetics had sued Alcon in 2008, accusing Alcon of anti-competitive behavior and alleging that Alcon used its "monopoly power" in the vitrectomy device market to boost sales of surgical illumination devices and related accessories, according to Synergetics' annual report. Alcon then countersued, alleging patent infringement and unfair competition
You may also be interested in...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.